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Abstract
Background: In non-dialysis chronic kidney disease (CKD) patients with dyslipidemia, statin therapy is recommended
to prevent cardiovascular complications. Dyslipidemia has been also shown to be an independent risk factor for the
progression of CKD. However, it is still unclear whether statin therapy exerts an inhibitory effect on renal deterioration
in CKD patients with dyslipidemia. The purpose of the present study was to examine possible therapeutic effects of
statin add-on therapy on renal function as well as parameters of lipid and glucose metabolism, arterial stiffness and
oxidative stress, in comparison to diet therapy, in CKD patients with dyslipidemia.
Methods: This study was a randomized, open-label, and parallel-group trial consisted of a 12-months treatment period
in non-dialysis CKD patients with alubuminuria and dyslipidemia. Twenty eight patients were randomly assigned either
to receive diet counseling alone (diet therapy group) or diet counseling plus pitavastatin (diet-plus-statin therapy
group), to achieve the LDL-cholesterol (LDL-C) target of <100 mg/dl.
Results: The statin treatment by pitavastatin was well tolerated in all of the patients without any significant adverse
events and the average dose of pitavastatin was 1.0 ± 0.0 mg daily after treatment. After the 12-months treatment
period, LDL-C was significantly lower in the diet-plus-statin therapy group compared with the diet therapy group
(diet vs diet-plus-statin: LDL-C, 126 ± 5 vs 83 ± 4 mg/dL, P < 0.001). On the other hand, the diet-plus-statin therapy did
not significantly reduce albuminuria or delay the decline in eGFR compared with the diet therapy, and there was no
relationship between the change in LDL-C and the change in eGFR or albuminuria. However, diet therapy as well as
diet-plus-statin therapy exerted similar lowering effects on the pentosidine levels (diet therapy group, baseline vs
12 months: 40 ± 4 vs 24 ± 3 ng/mL, P = 0.001; diet-plus-statin therapy, 46 ± 7 vs 34 ± 6 ng/mL, P = 0.008). Furthermore,
the results of multivariate regression analysis indicated that the change in pentosidine was a significant contributor to
the change in eGFR (β = −0.536, P = 0.011).
Conclusions: Although statin add-on therapy did not show additive renal protective effects, the diet therapy as well as
the diet-plus-statin therapy could contribute to the reduction in plasma pentosidine in CKD patients with albuminuria
and dyslipidemia.
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Background
The prevalence of chronic kidney disease (CKD) has
been increasing all over the world, and CKD patients are
frequently complicated with dyslipidemia. Dyslipidemia
is reportedly associated with cardiovascular complica-
tions which are the most common cause of death in
CKD patients, and statin is recommended for the treat-
ment of dyslipidemia to prevent cardiovascular complica-
tions in non-dialysis CKD patients with dyslipidemia [1].
Dyslipidemia has been also shown to be an independent
risk factor for the progression of CKD [2, 3]. In large
observational studies, dyslipidemia is a risk factor for the
initiation and progression of CKD [4, 5]. In addition, previ-
ous meta-analysis showed that statins for treatment of dys-
lipidemia may be beneficial for reduction of albuminuria
and inhibition of renal deterioration in CKD patients [6, 7].
The results of basic research studies showed that reno-
protective effects of statins would be, at least partly, due to
the amelioration of inflammatory and fibrotic responses in
the kidney via its inhibitory effects on oxidative stress,
advanced glycation end product (AGE), monocyte
chemoattractant protein-1 (MCP-1), and transforming
growth factor-β (TGF-β) [8–11].
Therefore, these accumulated findings imply that a
treatment for lipid abnormality might prevent the pro-
gression of CKD, and it is expected that statin therapy
for treating dyslipidemia could slow the progression of
renal deterioration. However, there is a lack of random-
ized controlled trials to directly compare the therapeuic
efficacy of standard diet therapy and statin add-on
therapy, or to determine the clinical target of serum
low-density lipoprotein cholesterol (LDL-C) level for
the prevention of CKD progression, particularly in CKD
patients with mild dyslipidemia. Although a recent ran-
domized controlled trial “The ASsessment of clinical
Usefulness in CKD patients with Atorvastatin (ASUCA)
study” is designed to determine whether statin exerts
protective effects on renal function including estimated
glomerular filtration rate (eGFR) and urine albumin-to-
creatinine ratio (UACR) in CKD patients with dyslipid-
emia, the main results have not been reported yet [12].
In the present study, we examined possible therapeutic
effects of statin add-on therapy on parameters of renal
function such as eGFR and UACR, as well as parame-
ters of lipid and glucose matabolism, oxidative stress
and arterial stiffness, in comparison to diet therapy, in
CKD patients with albuminuria and dyslipidemia.
Methods
Study design
This study was a randomized, open-label, and parallel-
group trial comparing the therapeutic efficacy of diet
therapy and diet-plus-statin therapy in non-dialysis
CKD patients with albuminuria and dyslipidemia. It
was conducted in accordance with the ethical princi-
ples of the Declaration of Helsinki and was approved
by the ethics committees of Yokohama City University
Hospital. The study was registered at the Clinical Trial
Registry of University Hospital Information Network
(UMIN Clinical Trials Registry: UMIN000002526; http://
www.umin.ac.jp/ctr/).
Study participants
CKD patients with dyslipidemia who had no history of
treatment with lipid-lowering agents were eligible for the
study if they were ≥20 years, with LDL-C ≥100 mg/dl and
albuminuria catogories A2 or A3 (UACR ≥ 30 mg/g-
creatinine). The estimated GFR (eGFR) was calculated
using a revised equation for the Japanese population
[13]. Exclusion criteria included CKD patients of G5
category (eGFR < 15 mL/min/1.73 m2) or on dialysis,
uncontrolled type 1 or type 2 diabetes, hypothyroidism,
and a history of CVD, and hypersensitivity to pitavastatin.
All of the patients provided written informed consent
before participation in the study, and follow-up was
undertaken by each investigator.
Study treatment
The eligible patients were randomly assigned either to
receive diet counseling alone (diet therapy group) or diet
counseling plus pitavastatin therapy (diet-plus-statin
therapy group). In both therapy groups, patients were
instructed to restrict the energy intake according to their
pathological conditions and needs (25–30 kcal/kg-standard
body weight/day), and take a diet including 25 % of energy
from fat, <300 mg cholesterol daily and <25 g alcohol daily.
Patients in diet-plus-statin therapy group were initially
given 1 mg of pitavastatin once daily and the dose of pita-
vastatin was titrated up to 4 mg daily as needed during the
12 months active treatment period, to achieve the LDL-C
level < 100 mg/dl. Laboratory measurements, clinic BP, and
adverse events were estimated at baseline and after 6 and
12 months of treatment. Brachial-ankle pulse wave velocity
(baPWV) was measured at baseline and after 12 months of
treatment.
Measurement of clinic BP and baPWV
The clinic BP was measured in a sitting position using
a calibrated standard mercury sphygmomanometer and
the recommended cuff size. Two measurements were
taken at 1–2 min intervals, and their average was
regarded as the clinic BP. The baPWV values were deter-
mined by a PP analyzer (model: BP-203-RPE2; Omron
Healthcare, Kyoto, Japan), as described previously [14–16].
Pulse volume waveforms were recorded with sensors placed
over the right brachial artery and both tibial arteries. The
baPWV values obtained by this method are reportedly
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correlated with the aortic PWV determined by the catheter
method [17].
Laboratory measurement
Blood and urine sampling were performed in the morning
after an overnight fast. Plasma pentosidine was deter-
mined using an ELISA kits (SRL laboratory, Tokyo, Japan).
Other parameters were determined by routine methods in
the Department of Clinical Chemistry, Yokohama City
University School Hospital.
Statistical analysis
Data were expressed as the mean ± SE or as a percentage.
Significant differences between the therapy groups were
assessed by unpaired t-test or nonparametric analysis using
the Wilcoxon U test for variables that were not normally
distributed. Differences between the therapy groups for cat-
egorical variables were analyzed using the Chi-square test.
A repeated-measures ANOVA model was utilized continu-
ous variables obtained during the 12 months of treatment.
SPSS18.0 statistical software was used for statistical analysis.
A value of P < 0.05 was considered statistically significant.
Results
Patient characteristics
Thirty one patients with CKD and dyslipidemia were
screened for eligibility from September 2009 to January
2011. At the inclusion visit, two patients did not fulfill
the selection criteria. One patient was lost to follow-up
before randomization. The causes of CKD were chronic
glomerulonephritis (N = 13), hypertensive nephrosclero-
sis (N = 12), diabetic nephropathy (N = 3) and other
causes (N = 3). The eligible patients were randomly
assigned to receive diet counseling alone (diet therapy
group, N = 14) or diet counseling plus pitavastatin ther-
apy (diet-plus-statin therapy group, N = 14). Table 1
shows the baseline characteristics of the participants.
There was a significant difference in aspartate trans-
aminase (AST) at baseline between the two therapy
groups, and the other parameters in the baseline charac-
teristics were similar in the two therapy groups. The
anti-hypertensive and other medications are summarized
in Table 2, and there were no significant differences be-
tween the diet therapy group and diet-plus-statin therapy
group. The statin treatment by pitavastatin was well toler-
ated in all of the patients without any significant adverse
events and the average dose of pitavastatin was 1.0 ±
0.0 mg daily after a period of 12 months of treatment.
Lipid and glucose metabolism
Table 3 shows the parameters of lipid and glucose metab-
olism at baseline and after 6 and 12 months of treatment.
There were no significant differences in the parameters of
lipid metabolism including total cholesterol (TC), LDL-C,
high-density lipoprotein cholesterol (HDL-C) and tri-
glyceride between the two groups at baseline. After
12 months of treatment, TC was significantly reduced
in the diet-plus-statin therapy group (baseline vs 12 months:
TC, 207 ± 7 vs 157 ± 5 mg/dL, P < 0.001), but not in the
diet therapy group (baseline vs 12 months: TC, 211 ± 6 vs
201 ± 6 mg/dL, P = 0.187; Table 3). With respect to the
therapeutic efficacy to achieve the target LDL-C control
after the treatment, while the reduction in LDL-C in the
diet therapy group did not reach the statistical significance
(baseline vs 12 months: LDL-C, 139 ± 6 vs 126 ± 5 mg/dL,
P = 0.055; Table 3), LDL-C in the diet-plus-statin therapy
group was significantly reduced so as to reach the LDL-C
target of <100 mg/dl (baseline vs 12 months: LDL-C, 136 ±
6 vs 83 ± 4 mg/dL, P < 0.001; Table 3). Furthermore, al-
though HDL-C and triglyceride were similar in the
two groups after the treatment period (diet vs diet-
plus-statin: HDL-C, 56 ± 4 vs 57 ± 5 mg/dL, P = 0.775;
triglyceride, 149 ± 21 vs 122 ± 18 mg/dL, P = 0.252; Table 3),
TC and LDL-C in the diet-plus-statin therapy group were
significantly lower than those in the diet therapy group after
the 12-months treatment period (diet vs diet-plus-statin:
TC, 201 ± 6 vs 157 ± 5 mg/dL, P < 0.001; LDL-C, 126 ± 5 vs
83 ± 4 mg/dL, P < 0.001; Table 3). The parameters of glu-
cose metabolism including fasting plasma glucose and
HbA1C were comparable in the two therapy groups before
and after the treatment period (Table 3).
In addition, the parameters of hepatic function including
AST and alanine transaminase (ALT) and the parameter
of muscle damage including creatine kinase (CK) did not
increase after 6 and 12 months of treatment in the both
groups, and there was no statistically significant difference
between the two groups during the whole active treatment
period (diet vs diet-plus-statin: AST, 27 ± 2 vs 22 ± 2 U/L,
P = 0.290; ALT, 24 ± 3 vs 26 ± 6 U/L, P = 0.849; CK, 161 ±
54 vs 114 ± 16 U/L, P = 0.585; Table 3).
Renal function and oxidative stress
Table 4 shows the parameters of renal function and oxi-
dative stress at baseline and after 6 and 12 months of
treatment. With respect to the parameters of renal func-
tion, eGFR and UACR were comparable in the diet-plus-
statin and diet therapy groups at baseline (Table 4). After
12 months of treatment, eGFR showed similar decreases
in the diet-plus-statin and diet therapy groups without
significant differences between the two groups (diet vs
diet-plus-statin: eGFR, 45.9 ± 4.3 vs 45.1 ± 5.3 mL/min/
1.73 m2, P = 0.924; Table 4). In addition, diet-plus-statin
therapy did not affect UACR and there were no signifi-
cant differences in UACR between the two groups after
12 months of treatment (diet vs diet-plus-statin: UACR,
687 ± 249 vs 557 ± 186 mg/g-Cr, P = 0.779; Table 4).
With respect to a maker of oxidative stress, pentosidine
was significantly reduced in both groups after the treatment
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Table 1 Demographic characteristics of the study groups at baseline
Diet (n = 14) Diet-plus-statin (n = 14) P value
Age (years) 63.9 ± 3.3 60.6 ± 3.4 0.492
Gender (female/male) 4/10 4/10 0.661
Body mass Index (kg/m2) 24.4 ± 0.7 24.3 ± 0.9 0.934
Current smoking (n (%)) 1 (7) 2 (14) 0.500
Alcohol (n (%)) 4 (29) 3 (21) 0.500
Diabetes mellitus (n (%)) 4 (29) 5 (36) 0.500
Hypertention (n (%)) 12 (86) 12 (86) 0.702
Cerebrovascular disease (n (%)) 0 (0) 1 (7) 0.500
Ischemic heart disease (n (%)) 0 (0) 1 (7) 0.500
Cause of CKD (n (%)): 0.318
Diabetic nephropathy 1 (7) 2 (14)
Chronic glomerulonephritis 6 (43) 7 (50)
Nephrosclerosis 6 (43) 4 (29)
Others 1 (7) 1 (7)
Systolic BP (mmHg) 133 ± 4 127 ± 4 0.306
Diastolic BP (mmHg) 79 ± 2 76 ± 2 0.435
Heart rate (beats/min) 69 ± 3 74 ± 2 0.239
Plasma glucose (mg/dL) 113 ± 7 107 ± 4 0.614
HbA1c (%) 5.6 ± 0.1 5.6 ± 0.1 0.946
TC (mg/dL) 211 ± 6 207 ± 7 0.620
LDL-C (mg/dL) 139 ± 6 136 ± 6 0.797
HDL-C (mg/dL) 56 ± 3 56 ± 4 0.966
TG (mg/dL) 145 ± 14 154 ± 20 0.715
AST (U/L) 24 ± 1 20 ± 1 0.035
ALT (U/L) 22 ± 2 20 ± 3 0.265
Creatine kinase (U/L) 110 ± 13 106 ± 13 0.946
Serum creatinine (mg/dL) 1.2 ± 0.1 1.3 ± 0.1 0.593
Estimated GFR (mL/min/1.73 m2) 50.1 ± 4.9 48.6 ± 4.7 0.827
GFR category (n (%)): 0.500
G1 1 (7) 0 (0)
G2 2 (14) 4 (29)
G3a 5 (36) 3 (21)
G3b 5 (36) 6 (43)
G4 1 (7) 1 (7)
G5 0 (0) 0 (0)
UACR (mg/g-Cr) 1025 ± 465 801 ± 254 0.946
Albuminuria category (n (%)): 1.000
A2 7 (50) 7 (50)
A3 7 (50) 7 (50)
Values are means ± SE or number (percentage). CKD chronic kidney disease, BP blood pressure, TC total cholesterol, LDL-C low-density lipoprotein cholesterol,
HDL-C high-density lipoprotein cholesterol, TG triglyceride, AST aspartate transaminase, ALT alanine transaminase, GFR glomerular filtration rate, UACR urine
albumin-to-creatinine ratio
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(diet therapy group, baseline vs 12 months: 40 ± 4 vs 24 ±
3 ng/mL, P = 0.001; diet-plus-statin therapy, 46 ± 7 vs 34 ±
6 ng/mL, P = 0.008), and there was no significant difference
between the two groups (diet vs diet-plus-statin: 24 ± 3 vs
34 ± 6 ng/mL, P = 0.214; Table 4).
Blood pressure and arterial stiffness
Clinic blood pressure (BP) and brachial-ankle pulse wave
velocity (baPWV) are shown in Table 5. At baseline,
there were no significant differences in the clinic BP and
baPWV between the two groups. During the active treat-
ment period, both clinic BP and baPWV did not exhibit
significant changes in the diet-plus-statin therapy group
as well as the diet therapy group (Table 5). Consequently,
systolic and diastolic BP did not differ between the two
groups after 12 months of treatment (diet vs diet-plus-
statin: systolic BP, 130 ± 4 vs 130 ± 4 mmHg, P = 0.753; dia-
stolic BP, 81 ± 2 vs 77 ± 2 mmHg, P = 0.413; Table 5). In
addition, baPWV was comparable in the diet therapy group
and diet-plus-statin therapy group after the treatment
Table 2 Medication in the study groups at baseline
Diet (n = 14) Diet-plus-statin (n = 14) P value
Antihypertensive agents (n (%))
Angiotensin II receptor blockers 12 (86) 10 (71) 0.324
Angiotensin-converting enzyme inhibitors 2 (14) 0 (0) 0.241
Calcium-channel blockers 10 (71) 8 (57) 0.430
Diuretics 4 (29) 3 (21) 0.500
β-blockers 4 (29) 3 (21) 0.500
α-blockers 1 (7) 0 (0) 0.500
Central sympatholytic agents 0 (0) 1 (7) 0.500
Glucose-lowering agents (n (%))
Insulin and insulin analougues 0 (0) 0 (0) -
Sulfonylureas 0 (0) 2 (14) 0.241
α-glucosidase inhibitors 3 (21) 1 (7) 0.298
Biguanides 1 (7) 0 (0) 0.500
Thiazolidinediones 0 (0) 1 (7) 0.500
Lipid-lowering agents (n (%)) 0 (0) 0 (0) -
Antiplatelet agents (n (%)) 2 (14) 3 (21) 0.500
Values are number (percentage)
Table 3 Comparison of the parameters of lipid and glucose metabolism, hepatic function and muscle damage in the diet therapy
and diet-plus-statin groups
Diet Diet-plus-statin
Baseline 6 months 12 months Baseline 6 months 12 months
Lipid metabolism:
TC (mg/dL) 211 ± 6 220 ± 9 201 ± 6 207 ± 7 171 ± 5**† 157 ± 5**††
LDL-C (mg/dL) 139 ± 6 139 ± 7 126 ± 5 136 ± 6 94 ± 4**† 83 ± 4**††
HDL-C (mg/dL) 56 ± 3 57 ± 4 56 ± 4 56 ± 4 61 ± 5 57 ± 5
TG (mg/dL) 145 ± 14 198 ± 33 149 ± 21 154 ± 20 132 ± 19 122 ± 18
Glucose metabolism:
Glucose (mg/dL) 113 ± 7 108 ± 4 115 ± 7 107 ± 4 108 ± 4 115 ± 9
HbA1C (%) 5.6 ± 0.1 5.6 ± 0.2 5.5 ± 0.2 5.6 ± 0.1 5.7 ± 0.1 5.6 ± 0.2
Hepatic and muscle enzymes:
AST (U/L) 24 ± 1 27 ± 2 27 ± 2 20 ± 1† 26 ± 5 22 ± 2
ALT (U/L) 22 ± 2 25 ± 2 24 ± 3 20 ± 3 29 ± 8 26 ± 6
CK (U/L) 110 ± 13 128 ± 20 161 ± 54 106 ± 13 131 ± 24 114 ± 16
Values are means ± SE. TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglyceride, AST aspartate
transaminase, ALT alanine transaminase, CK creatine kinase. **P < 0.001 vs baseline; †P < 0.05, ††P < 0.001 vs diet therapy alone
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period (diet vs diet-plus-statin: baPWV, 1705 ± 87 vs
1833 ± 141 cm/sec, P = 0.218; Table 5).
Factors associated with renal function
To examine possible factors related to renal functional
regulation, we performed univariate and multivariate lin-
ear regression analyses. In univariate analysis, the change
in eGFR was inversely correlated with the change in
pentosidine (β = −0.580, P = 0.002; Table 6). However,
there was no significant relationship between the change
in eGFR and the change in LDL-C (β = 0.080, P = 0.684;
Table 6). Furthermore, the results of multivariate linear
regression analysis indicated that the change in pentosi-
dine was a significant contributor to the change in eGFR
(β = −0.536, P = 0.011; Table 6). On the other hands, the
change in UACR was not correlated with the change in
pentosidine or the change in LDL-C in both univariate
and multivariate linear regression analyses (Table 7).
Discussion
In the present study, although the diet-plus-statin ther-
apy efficiently lowered LDL-C without an increase in ad-
verse events in CKD patients with albuminuria and
dyslipidemia, no significant additive beneficial effects on
parameters of renal function (UACR, eGFR) were ob-
served in the diet-plus-statin therapy compared to the diet
therapy alone.
Concerning possible renal protective effects of statins,
the results of previous studies including meta-analysis,
which examined the benefits of statin therapy on renal
function, are not consistent [7, 18, 19]. In a post-hoc
analysis of “Management of Elevated Cholesterol in the
Primary Prevention Group of Adult Japanese Study”
(MEGA) study, pravastatin exerted a beneficial effect on
proteinuria in patients with hypercholesterolaemia [20].
The result of other post hoc analysis of “Greek Atorva-
statin and Coronary Heart Disease Evaluation” (GREACE)
study showed that atorvastatin therapy prevented renal
functional decline in untreated dyslipidemia patients [21].
On the other hand, it was reported that rosuvastain ther-
apy increased proteinuria in the general population [22],
and the results of a post-hoc analysis of “Prevention of
Renal and Vascular End-stage Disease Intervention Trial”
(PREVEND-IT) study showed that pravastatin did not exert
beneficial effects on albuminuria and eGFR [23]. Moreover,
in the recent two meta-analyses, lipid-lowering therapy
with statin did not improve kidney outcomes [18, 19].
Therefore, in terms of the prevention of CKD progres-
sion, there is no direct clinical evidence identifying bene-
ficial effects of statin therapy to inhibit or reverse CKD
progression, and there are still insufficient data based on
randomized clinical trial to recommend the target for
acceptable LDL-C level in CKD patients. In line with
this situation, in the present study, the diet-plus-statin
therapy did not significantly reduce albuminuria or inhibit
the decrease in eGFR compared with the diet therapy in
CKD patients with dyslipidemia. In addition, univariate
and multivariate linear regression analysis showed no sig-
nificant correlation between change in LDL-C and change
in eGFR or UACR.
A possible reason for the lack of renal protective effects
by statin therapy in the present study may be due to
characteristics of lipid metabolism of participants. Since the
inclusion criteria for LDL-C level was LDL-C ≥100 mg/dl,
Table 4 Comparison of the parameters of renal function and oxidative stress in the diet therapy and diet-plus-statin groups
Diet Diet-plus-statin
Baseline 6 months 12 months Baseline 6 months 12 months
Renal function:
Estimated GFR (mL/min/1.73 m2) 50.1 ± 4.9 45.1 ± 4.3* 45.9 ± 4.3* 48.6 ± 4.7 45.6 ± 4.5* 45.1 ± 5.3*
UACR (mg/g-Cr) 1025 ± 465 671 ± 220 687 ± 249 801 ± 254 714 ± 233 557 ± 186
Oxidative stress:
Pentosidine (ng/mL) 40 ± 4 28 ± 3* 24 ± 3* 46 ± 7 38 ± 7 34 ± 6*
Values are means ± SE. GFR glomerular filtration rate, UACR urine albumin-to-creatinine ratio. *P < 0.05 vs baseline
Table 5 Comparison of clinic BP and arterial stiffness in the diet therapy and diet-plus-statin groups
Diet Diet-plus-statin
Baseline 6 months 12 months Baseline 6 months 12 months
Clinic BP:
Systolic BP (mmHg) 133 ± 4 131 ± 4 130 ± 4 127 ± 4 133 ± 5 130 ± 4
Diastolic BP (mmHg) 79 ± 2 81 ± 2 81 ± 2 76 ± 2 79 ± 3 77 ± 2
Arterial stiffness:
baPWV (cm/s) 1661 ± 86 - 1705 ± 87 1919 ± 144 - 1833 ± 141
Values are means ± SE. BP blood pressure, baPWV brachial-ankle pulse wave velocity
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baseline LDL-C levels in the diet and diet-plus-statin ther-
apy groups were 139 ± 6 and 136 ± 6 mg/dL, respectively,
thereby indicating that the study participants belonged to
“mild” dyslipidemia. With respect to the contribution of
baseline LDL-C level to the progression of renal injury, it
has been reported that circulating LDL-C has a charge af-
finity for glycoaminoglycans in the glomerular basement
membrane and cause a glomerulosclerosis and tubulointer-
stitial injury, indicating an important role of high LDL-
C level in the progression of kidney desease defined as
“lipid nephrotoxicity” [24, 25]. In fact, epidemiologic evi-
dence indicates that greater baseline LDL-C levels are re-
lated to the more rapid progression of CKD [4, 5].
Therefore, it would be possible that the “mild “range of
dyslipidemia at baseline in the participants masked the
renoprotective effects by the statin thepary in the present
study. Additionally, dietary changes by dietary therapy
might affect these results. It has been reported that some
nutraceuticals and functional foods such as nuts and fish
oil could be beneficial for dyslipidemia and vascular func-
tion in situations where statins cannot be used [26].
As an important finding in the present study, diet
therapy as well as diet-plus-statin therapy exerted simi-
lar lowering effects on the pentosidine levels in CKD
patients with dyslipidemia. Furthermore, there was an
inverse correlation between the change in pentosidine
and the change in eGFR. These results suggest possible
beneficial effects of diet therapy with or without statin
therapy to suppress oxidative stress, with subsequent
improving influence on the kidney injury in CKD patients
with dyslipidemia.
The mechanisms responsible for the inverse correlation
between the change in pentosidine and the change in eGFR
may be due to improvements in systemic inflammatory
state by the decease in pentosidine levels in CKD patients.
Pentosidine is an AGE, formed by glycosylation and oxida-
tion, that accumulates markedly in advanced stages of CKD
[27]. Oxidative stress play a crucial role in the pathogenesis
and progression of endothelial dysfunction, CKD and
cardiovascular disease [28, 29]. Previous studies also
showed a relationship between pentosidine and the markers
of inflammation and monocyte activation [30]. In addition,
plasma pentosidine was strongly correlated with the
markers of inflammation, such as CRP, fibrinogen and
IL-6 and the levels of soluble vascular cellular adhesion
molecule-1 (sVCAM-1) which play an important role in
the development of atherosclerosis [31, 32]. Thus, AGE,
oxidative stress and proinflammatory cytokines may con-
tribute to the systemic inflammation in CKD patients with
dyslipidemia and accelerate the progression of CKD and
atherosclerosis [27, 33–37].
To the best of our knowledge, this is the first report to
show that diet therapy for dyslipidemia in CKD patients
exerted a beneficial effect to reduce the plasma pentosi-
dine level which could affect the CKD progression. AGE
is known to be formed by a non-enzymatic reaction in
diet [38], and dietary AGE have been considered to con-
tribute to the increases in serum AGE concentration
[39, 40]. With respect to the relationship between diet
and pentosidine, diet-derived pentosidine is reportedly
one possible origin of plasma pentosidine [39, 41].
However, possible effects of diet therapy for dyslipidemia
on plasma pentosidine levels had never been examined
to date. The results of the present study for the first time
showed that the standard diet therapy with or without
statin therapy could contribute to the reduction in
plasma pentosidine, even without using specially prepared
pentosidine-restricted diet, in non-dialysis CKD patients
with albuminuria and dyslipidemia.
There were several limitations in this study. Firstly,
this study was not a double-blinded placebo-controlled
trial. It is difficult to assess the safety of diet therapy and
diet-plus-statin therapy because of the absence of placebo
Table 7 Univariate and multivariate linear regression analyses of
clinical factors affecting the change in UACR
Variables Univariate Multivariate
β P β P
Change in eGFR 0.286 0.140 0.390 0.199
Change in pentosidine −0.045 0.830 0.156 0.594
Change in LDL-C 0.216 0.271 0.239 0.354
Change in systolic BP 0.032 0.872 0.390 0.149
Age 0.091 0.645 −0.098 0.725
Sex (male:1, female:0) −0.067 0.734 −0.262 0.323
BMI 0.101 0.610 0.090 0.697
Model R2 = 0.197
R2 = coefficient of determination. UACR urine albumin-to-creatinine ratio,
eGFR estimated glomerular filtration rate, LDL-C low-density lipoprotein
cholesterol, BP blood pressure
Table 6 Univariate and multivariate linear regression analyses of
clinical factors affecting the change in eGFR
Variables Univariate Multivariate
β P β P
Change in UACR 0.286 0.140 0.243 0.199
Change in pentosidine −0.580 0.002 −0.536 0.011
Change in LDL-C 0.080 0.684 −0.125 0.543
Change in systolic BP −0.256 0.189 −0.371 0.076
Age 0.093 0.636 0.196 0.365
Sex (male:1, female: 0) 0.176 0.370 0.183 0.384
BMI 0.148 0.451 0.052 0.776
Model R2 = 0.500
R2 = coefficient of determination. eGER estimated glomerular filtration rate,
UACR urine albumin-to-creatinine ratio, LD BP blood pressure, LDL-C low-density
lipoprotein cholesterol, HDL-C, high-density lipoprotein cholesterol
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groups. Secondly, the sample size of this study was small,
and the population was heterogeneous for the cause of
CKD including nondiabetic kidney diseases and diabetic
kidney disease. Therefore, it should be emphasized that
we cannot make any conclusive statement with respect to
the relative efficacy of the statin add-on therapy for lipid
lowering effects as well as renal and vascular protective ef-
fects, in comparison to diet therapy, in CKD patients with
mild dyslipidemia. Definitely the present study should be
classified as a pilot study for executing head-to-head clin-
ical trials including the placebo group with increased
number of participants of homogeneous population in the
background of CKD in the near future. Thirdly, we did
not investigate the actual totality of dietary changes in par-
ticipants between before and after the interventions, al-
though we set the dietary goal. This limitation might make
it difficult to evaluate the statin add-on effect exactly.
Additionally, since diet therapy may exert several effects
on glucose metabolism, adipose tissue function and other
systems in addition to lipid metabolism, it is needed to
examine the effects of diet therapy on other parameters
such as insulin resistance, adipokines and endothelial
function in further studies.
Conclusions
In summary, the diet-plus-statin therapy did not exert
significantly additive beneficial effects on parameters of
renal function (UACR, eGFR), compared to the diet
therapy, in spite of efficient LDL-C lowering by the diet-
plus-statin therapy without an increase in adverse events
in CKD patients with albuminuria and dyslipidemia.
However, diet therapy as well as diet-plus-statin therapy
exerted similar lowering effects on the pentosidine levels
in these patients. Furthermore, the change in plasma
pentosidine was inversely correlated with the change in
eGFR. These results suggest that diet therapy as well as
statin therapy are important as multifactorial treatment
strategy for non-dialysis CKD patients with albuminuria
and dyslipidemia.
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